The safety of phosphate binders.
Disturbances of mineral metabolism occur during the early stages of chronic kidney disease. As renal function worsens, excess dietary phosphorus accumulates and blood levels increase, that can be clearly seen when the glomerular filtration rate has fallen below 30 ml/min/1.73 m2. In patients with end stage renal disease, standard dialysis (three times/week) falls far short of removing adequate amounts of absorbed phosphorus; therefore, hyperphosphataemia is found in the majority of these patients. Hyperphosphataemia has long been associated with progression of secondary hyperparathyroidism and renal osteodystrophy, it can also lead to soft-tissue and vascular calcification. Recent observational data have associated hyperphosphataemia with increased cardiovascular mortality among dialysis patients. Adequate control of serum phosphorus remains a cornerstone in the clinical management and, despite the growing amount of available therapeutic options, achievement of NFK/KDOQI targets for mineral metabolism remain poor. Several reasons may explain the failure to adequately treat hyperphosphataemia: poor compliance with diet and phosphate binder prescriptions are common causes. Also, factors related with cost, tolerance, palatability, safety and efficacy are important. In this article, the authors review the advantages and drawbacks of conventional and emerging therapies in phosphorous binding.
Almirall
Jaume
J
Institut Universitari Parc Taulí, Nephrology Service, Corporació Parc Taulí, Parc Taulí s/n 08208, Sabadell, Barcelona, Spain. jalmirall@cspt.es
Daly
Jaume Almirall
JA
Valenzuela
Maria Pau
MP
Mujica
Maria Pau Valenzuela
MP
D002318:Cardiovascular Diseases / Q000209:etiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D028044:Phosphate-Binding Proteins / Q000627:therapeutic use*; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000378:metabolism / Q000503:physiopathology; D011073:Polyamines / Q000627:therapeutic use; D006435:Renal Dialysis; D000069603:Sevelamer
D028044:Phosphate-Binding Proteins; D011073:Polyamines; D000069603:Sevelamer